Long-term safety and efficacy of bisphosphonate therapy in advanced lung cancer with bone metastasis

Data from a retrospective, observational study of 359 patients who had received bisphosphonate treatment for ≤ versus ≥ 24 months demonstrated significantly lower adverse events in the ≤ 24-month group (P = 0.008), and that bisphosphonate treatment for longer than 24 months was a potential risk factor for adverse events (P = 0.05).